Skip to main content

Advertisement

SpringerLink
Log in

Treatment of Patients with a History of Heparin-Induced Thrombocytopenia and Anti-Lepirudin Antibodies with Argatroban

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

An Erratum to this article was published on 01 October 2005

Abstract

Patients with heparin-induced thrombocytopenia (HIT) type II require anticoagulation with non-heparin immediate acting anticoagulants. Danaparoid may cross react with HIT-antibodies and lepirudin may generate anti-lepirudin antibodies influencing anticoagulation. We hypothesised, that the synthetic small molecular thrombin inhibitor argatroban does not induce immunoglobulins reacting towards lepirudin in patients with anti-lepirudin antibodies in the history and that titration of the anticoagulation may be easier with argatroban.

We report on the treatment of four patients of a study, which was terminated prematurely due to official warnings for a repeated use of lepirudin. Two patients each received argatroban and lepirudin intravenously. A blinded assessor adjusted the doses of the anticoagulants to 1.5–3.0 fold prolongation of the aPTT. Ecarin clotting time (ECT), concentrations of lepirudin (ELISA) and of argatroban (gaschromatoraphy with mass spectrometry,) and the generation of lepirudin antibodies (ELISA) were measured.

APTT-adjusted dosages for argatroban was 2.0–2.6 μg/kg⋅ min and for lepirudin 48–149 μ g/kg⋅ h. ECT was prolonged 2.1 to 4.5-fold with lepirudin and 4 to 7-fold with argatroban. The concentration of lepirudin ranged between 750 and 1500 ng/ml and of argatroban between 400 and 1100 ng/ml. Patients on argatroban did not generate immunoglobulin IgG reacting towards lepirudin in contrast to both patients on lepirudin who developed anti-lepirudin antibodies. Both treatments were well tolerated.

Despite the low number of patients argatroban seems to lead to a more stable anticoagulant response than lepirudin resulting in a lower variability of the dosage for prophylaxis or treatment of thromboembolism of patients with a history of HIT and lepirudin antibodies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: A critical review. Arch Intern Med 2004;164:361–364.

    Article  PubMed  Google Scholar 

  2. Chong BH, Pitney WR, Castaldi PA. Heparin-induced thrombocytopenia: Association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation. Lancet 1982;2:1246–1249.

    Article  PubMed  Google Scholar 

  3. Greinacher A, Völpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. The HIT Investigators Group. Circulation 1999;99:73–80.

    PubMed  Google Scholar 

  4. Harenberg J, Huhle G, Piazolo L, Wang LU, Heene DL. Anticoagulation in patients with heparin-induced thrombocytopenia type II. Semin Thromb Hemost 1997;23:189–196.

    PubMed  Google Scholar 

  5. Harenberg J, Hoffmann U, Huhle G, Song XH, Wang LC. Treatment of an acute flush reaction caused by subcutaneous r-hirudin with pegylated hirudin. Br J Haematol 2000;108 528–530.

    Article  PubMed  Google Scholar 

  6. Lewis BE, Wallis DE, Berkowitz SD, et al. for the ARG 911 Study Investigators: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103;1838–1843.

    PubMed  Google Scholar 

  7. Walenga JM, Ahmad S, Hoppensteadt D, Iqbal O, Hursting MJ, Lewis BE. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 2002;105:401–405.

    Article  PubMed  Google Scholar 

  8. Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991;66:734–736.

    PubMed  Google Scholar 

  9. Song X, Huhle G, Wang L, Hoffmann U, Harenberg J. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation 1999;100:1528–1532.

    PubMed  Google Scholar 

  10. Huhle G, Hoffmann U, Song X, Wang LC, Heene DL, Harenberg J. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Br J Haematol 1999;106; 195–201.

    Article  PubMed  Google Scholar 

  11. Greinacher A, Eichler P, Albrecht D, Strobel U, Pötzsch B, Eriksson B. Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: Incidence and clinical relevance. Blood 2003;101:2617–2619.

    Article  PubMed  Google Scholar 

  12. Harenberg J, Huhle G, Wang C, Hoffmann U, Song XH. Re-exposure to recombinant r-hirudin in antihirudin antibody-positive patients with a history of heparin-induced thrombocytopenia. Br J Haematol 2000;109:360–363.

    Article  PubMed  Google Scholar 

  13. Bircher AJ, Czendlik SH, Langauer Messmer S, Müller Ph, Howaldh. Acute urticaria caused by sub cutaneous recombinant hirudin: Evidence for an IgG-mediated hypersensitivity reaction. J Allergy Clin Immunol 1996;98:994–996.

    PubMed  Google Scholar 

  14. EMEA public health statement on refludan (lepirudin)—fatal anaphylactic reactions-. Document reference: EMEA/H/27717/02/2/en. http://www.emea.eu.int.

  15. Greinacher S, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003;108:2062–2065.

    Article  PubMed  Google Scholar 

  16. Close P, Bichler J, Kerry R, et al. Weak allergenicity of recombinant hirudin CGP39393 (REVASC) in immunocompetent volunteers: The European Hirudin in Thrombosis Group (HIT Group). Coron Art Dis 1994;5:943–949.

    Google Scholar 

  17. Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low molecular weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329–1335.

    Article  PubMed  Google Scholar 

  18. Wieder KJ, Palczuk NC, van Es T, David FF. Some properties of polyethylene glycan phenylalanine ammonia-lyase adducts. J Biol Chem 1979;254:12579–12583.

    PubMed  Google Scholar 

  19. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318–329.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. IV. Department of Medicine, University Hospital Mannheim, Ruprecht-Karls-University Heidelberg, Theodor-Kutzer-Ufer 1-3, D-68167, Mannheim, Germany

    Harenberg Job MD (Professor of Medicine)

  2. IV. Department of Medicine, University Hospital Mannheim, Ruprecht-Karls University Heidelberg, Theodor-Kutzer-Ufer, D-68167, Mannheim, Germany

    Jörg Ingrid MD, Fenyvesi Tivadar MD & Piazolo Lukas MD

Authors
  1. Harenberg Job MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jörg Ingrid MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fenyvesi Tivadar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Piazolo Lukas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Harenberg Job MD.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s11239-005-5113-0.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Job, H., Ingrid, J., Tivadar, F. et al. Treatment of Patients with a History of Heparin-Induced Thrombocytopenia and Anti-Lepirudin Antibodies with Argatroban. J Thromb Thrombolysis 19, 65–69 (2005). https://doi.org/10.1007/s11239-005-0942-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-005-0942-4

Search

Navigation